"This study is based on in vivo studies that have demonstrated a nearly 100% reduction in FXI levels for up to 6 months without bleeding events after a single subcutaneous administration," said Dr. Qunsheng Ji, Chief Executive Officer of Sirius Therapeutics. "The study will provide an opportunity to evaluate the potential of SRSD107 as a differentiated therapeutic agent for the global treatment of these common disorders."

The Phase 1 study for SRSD107, which is being conducted in healthy volunteers in Australia, is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SRSD107 at single elevated doses and multiple escalated doses.